News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. is pleased to announce its achievement of a score of 44 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment. This marks an improvement of 6 points compared to the previous assessment, with advancements observed across all three dimensions. (CSA Score as of November 27, 2024).
In the latest assessment, Porton’s scores increased by 3 points in the Environmental dimension, 5 points in the Social dimension, and 9 points in the Governance & Economic dimension. Significant progress was noted in areas such as Transparency and Reporting, Materiality, Climate Strategy, Labor Practices, Human Rights, and Supply Chain Management.
Guided by the ESG principles of "Green Development, Promoting Common Progress, Building a Healthy Society, and Enhancing Corporate Governance," Porton is dedicated to embedding ESG values into its corporate strategy and operations. In 2024, Porton further strengthened its ESG management by implementing various initiatives, including developing management systems, setting targets, and enhancing the quality of disclosures. Moving forward, Porton remains committed to practicing ESG principles and fostering sustainable development.
Others
More
News 2026-09-01
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.

News 2026-08-05
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.